New technology helps trace the origin of Huntington's disease

The first signs of Huntington's, an inherited disease that slowly deteriorates bodies and minds, don't typically surface until middle age. But new findings suggest that something in the brain might be amiss long before symptoms arise, and earlier than has ever been observed. Using a new technology, Rockefeller scientists were able to trace the causes of the disease back to early developmental stages when the brain has only just begun to form.

Developed in the lab of Ali Brivanlou, the Robert and Harriet Heilbrunn Professor, the system uses neuroloids--tiny, three-dimensional tissue cultures that serve as models for whole organs. The researchers create these cell clumps from human embryonic stem cells and manipulate them in the lab to study how developmental diseases arise.

Previous work in the Brivanlou lab found evidence that the disease arises in young neurons; but this latest study takes the developmental timeframe back even further, to the step in the brain's development when cellular uniformity gives way to the emergence of particular structures, a process called neurulation. When the researchers introduced into neuroloids a mutation known to cause Huntington's, it consistently caused dramatic effects with abnormally shaped tissue structures. "Something's collapsed," Brivanlou says.

The researchers have started using the technology to screen for drugs that prevent these abnormalities, an approach they hope will provide a powerful alternative to similar work being done in animal models.

This technology really opens a door toward identifying that mechanisms that govern brain development, understanding how they go awry in disease, and testing drugs that set these mechanisms back on the right course."

Ali Brivanlou, the Robert and Harriet Heilbrunn Professor

Source:
Journal reference:

Haremaki, T. et al. (2019) Self-organizing neuruloids model developmental aspects of Huntington’s disease in the ectodermal compartment. Nature Biotechnology. doi.org/10.1038/s41587-019-0237-5

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Neuroactive drugs show promising anti-glioblastoma effects in preclinical trials